Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Mifegyne

Phase 3Small molecule

KKarolinska Institutet

Mifegyne is one of 69 small molecule programs targeting Abortion. It is currently in Phase 3.

2

Indications

2

Total Trials

0

Active Trials

68

Competitors

Pipeline

Status by Indication[3][1]

Indication

AbortionActive, not recruiting

Uterine FibroidActive, not recruiting

AbortionPhase 3

Active, not recruiting

Uterine FibroidPhase 1

Active, not recruiting

Competition

Competitive Landscape

97 competitors in Abortion

#DrugCompanyPhaseTrials

Cytotec

Pitocin

Advil

Oxycontin

Dostinex

Enoxaparine

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Anerem

AAcacia Pharma Ltd

Spravato

IV Ketamine

MMinneapolis Veterans Affairs Medical Center

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Uterine Fibroid1 trial

The Effect of Mifepristone on Uterine Fibroids and Breast Tissue

Completed·KKarolinska Institutet·Phase 1·NCT00579475·30 enrolled

Abortion1 trial

Cervical Preparation for Surgical Abortion at 12-14 Weeks: a Prospective, Randomized, Evaluator-blinded, Multicenter, Controlled Comparison Between Mifepristone, Misoprostol and Their Combination

Unknown status·AAssistance Publique Hopitaux De Marseille·Phase 3·NCT01795599·198 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Mifegyne. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mifegyne compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mifegyne. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Karolinska Institutet company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: KKarolinska Institutet

Related News